NEWS ACCESS BIO

Access Bio, Inc. CareStart™ COVID-19 Detection Kits Efficacy in New SARS-CoV-2 Variant Omicron

NEWS
Author
Access BIO
Date
2021-12-08 00:12
Views
148

Access Bio, Inc. CareStart™ COVID-19 Detection Kits Efficacy in New SARS-CoV-2 Variant Omicron

Based on sequence analysis and Omicron recombinant protein test, Omicron variant does not have influence on the target region of  CareStart™ COVID-19 Rapid and PCR Tests.

Access Bio, Inc.’s CareStart™ COVID-19 MDx RT-PCR, CareStart™ COVID-19 Antigen Test, and CareStart™ COVID-19 Home Test can detect the mutated Omicron variant of SARS-CoV-2.

We are actively continuing to monitor and analyze variants of SARS-CoV-2 to ensure the performance of our tests and, based on the design of our tests, it is highly likely that our tests will continue to detect all variants of SARS-CoV-2.

We will do our best to contribute to mitigate of the spread of COVID-19 with our diagnostics, which have been proven to be able to detect mutated variants.